...
rprx-img

Royalty Pharma Plc, Common Stock

RPRX

NSQ

$24.843

-$0.28

(-1.11%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$14.80B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
9.8898
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.65M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
3.34%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.47
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$24.7 L
$30.92 H
$24.843

About Royalty Pharma Plc, Common Stock

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameRPRXSectorS&P500
1-Week Return-1.84%-3.39%0.2%
1-Month Return-2.64%-1.92%2.72%
3-Month Return-11.05%-10.54%7.31%
6-Month Return-5.6%-4.47%10.44%
1-Year Return-8.15%4.06%27.53%
3-Year Return-34.82%0.94%30.88%
5-Year Return-43.55%36.67%89.21%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.81B2.12B2.29B2.24B2.35B[{"date":"2019-12-31","value":77.05,"profit":true},{"date":"2020-12-31","value":90.12,"profit":true},{"date":"2021-12-31","value":97.24,"profit":true},{"date":"2022-12-31","value":95.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue1.02B88.11M23.00M5.67M560.66M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":8.64,"profit":true},{"date":"2021-12-31","value":2.26,"profit":true},{"date":"2022-12-31","value":0.56,"profit":true},{"date":"2023-12-31","value":55,"profit":true}]
Gross Profit794.93M2.03B2.27B2.23B1.79B[{"date":"2019-12-31","value":35.07,"profit":true},{"date":"2020-12-31","value":89.74,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.46,"profit":true},{"date":"2023-12-31","value":79.15,"profit":true}]
Gross Margin43.82%95.85%99.00%99.75%76.19%[{"date":"2019-12-31","value":43.93,"profit":true},{"date":"2020-12-31","value":96.09,"profit":true},{"date":"2021-12-31","value":99.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.38,"profit":true}]
Operating Expenses(808.92M)527.00M858.75M1.31B862.40M[{"date":"2019-12-31","value":-61.55,"profit":false},{"date":"2020-12-31","value":40.1,"profit":true},{"date":"2021-12-31","value":65.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":65.62,"profit":true}]
Operating Income2.62B1.59B1.43B977.50M1.49B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":60.8,"profit":true},{"date":"2021-12-31","value":54.54,"profit":true},{"date":"2022-12-31","value":37.26,"profit":true},{"date":"2023-12-31","value":56.88,"profit":true}]
Total Non-Operating Income/Expense(408.00M)(50.45M)(302.12M)(186.63M)93.04M[{"date":"2019-12-31","value":-438.51,"profit":false},{"date":"2020-12-31","value":-54.22,"profit":false},{"date":"2021-12-31","value":-324.71,"profit":false},{"date":"2022-12-31","value":-200.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income2.46B1.70B1.24B230.06M1.70B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":69.15,"profit":true},{"date":"2021-12-31","value":50.43,"profit":true},{"date":"2022-12-31","value":9.35,"profit":true},{"date":"2023-12-31","value":69.07,"profit":true}]
Income Taxes349.33M1.15B762.45M187.23M565.25M[{"date":"2019-12-31","value":30.46,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":66.47,"profit":true},{"date":"2022-12-31","value":16.32,"profit":true},{"date":"2023-12-31","value":49.28,"profit":true}]
Income After Taxes2.11B555.00M478.75M42.83M1.13B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":26.28,"profit":true},{"date":"2021-12-31","value":22.67,"profit":true},{"date":"2022-12-31","value":2.03,"profit":true},{"date":"2023-12-31","value":53.73,"profit":true}]
Income From Continuous Operations2.46B1.69B1.24B230.06M1.70B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":68.62,"profit":true},{"date":"2021-12-31","value":50.43,"profit":true},{"date":"2022-12-31","value":9.35,"profit":true},{"date":"2023-12-31","value":69.07,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income2.35B495.20M478.75M42.83M1.13B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":21.09,"profit":true},{"date":"2021-12-31","value":20.39,"profit":true},{"date":"2022-12-31","value":1.82,"profit":true},{"date":"2023-12-31","value":48.32,"profit":true}]
EPS (Diluted)-5.082.233.674.38[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":43.9,"profit":true},{"date":"2022-12-31","value":72.24,"profit":true},{"date":"2023-12-31","value":86.22,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RPRX
Cash Ratio 0.86
Current Ratio 1.54
Quick Ratio 2.21

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RPRX
ROA (LTM) 5.69%
ROE (LTM) 17.28%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RPRX
Debt Ratio Lower is generally better. Negative is bad. 0.43
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.38

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RPRX
Trailing PE 9.89
Forward PE 8.41
P/S (TTM) 6.53
P/B 1.62
Price/FCF NM
EV/R 7.48
EV/Ebitda 8.82
PEG 5.43

FAQs

What is Royalty Pharma Plc share price today?

Royalty Pharma Plc (RPRX) share price today is $24.843

Can Indians buy Royalty Pharma Plc shares?

Yes, Indians can buy shares of Royalty Pharma Plc (RPRX) on Vested. To buy Royalty Pharma Plc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RPRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Royalty Pharma Plc be purchased?

Yes, you can purchase fractional shares of Royalty Pharma Plc (RPRX) via the Vested app. You can start investing in Royalty Pharma Plc (RPRX) with a minimum investment of $1.

How to invest in Royalty Pharma Plc shares from India?

You can invest in shares of Royalty Pharma Plc (RPRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in RPRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Royalty Pharma Plc shares
What is Royalty Pharma Plc 52-week high and low stock price?

The 52-week high price of Royalty Pharma Plc (RPRX) is $30.92. The 52-week low price of Royalty Pharma Plc (RPRX) is $24.7.

What is Royalty Pharma Plc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Royalty Pharma Plc (RPRX) is 9.8898

What is Royalty Pharma Plc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Royalty Pharma Plc (RPRX) is 1.62

What is Royalty Pharma Plc dividend yield?

The dividend yield of Royalty Pharma Plc (RPRX) is 3.34%

What is the Market Cap of Royalty Pharma Plc?

The market capitalization of Royalty Pharma Plc (RPRX) is $14.80B

What is Royalty Pharma Plc’s stock symbol?

The stock symbol (or ticker) of Royalty Pharma Plc is RPRX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top